We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Comstock Resources
CRK
$3.89B
| $22.6M | 0.12% |
818,305
+389,657
| +91% | +$8.87M |
|
252
AT&T
T
$159B
| $22.5M | 0.12% |
778,335
+221,293
| +40% | +$6.1M |
|
|
GRDN
253
Guardian Pharmacy Services
GRDN
$2.5B
| $22.4M | 0.12% |
1,053,378
+632,175
| +150% | +$14.3M |
|
254
Toll Brothers
TOL
$13.6B
| $22.3M | 0.12% |
195,566
+34,796
| +22% | +$3.61M |
|
255
PPG Industries
PPG
$24.6B
| $22.2M | 0.12% |
195,266
+175,666
| +896% | +$19M |
|
256
argenx
ARGX
$53.4B
| $22.2M | 0.12% |
40,271
-49,525
| -55% | -$28.7M |
|
257
Delta Air Lines
DAL
$57.5B
| $22.1M | 0.12% |
450,198
-202,361
| -31% | -$9.29M |
|
258
Trevi Therapeutics
TRVI
$2.59B
| $22.1M | 0.12% |
4,046,435
+1,988,623
| +97% | +$12.4M |
|
259
Enliven Therapeutics
ELVN
$3.92B
| $22.1M | 0.12% |
1,100,657
+295,500
| +37% | +$5.59M |
|
260
Freeport-McMoran
FCX
$90B
| $21.9M | 0.12% |
505,970
-695,227
| -58% | -$26.4M |
|
261
Fortive
FTV
$17.9B
| $21.9M | 0.12% |
419,955
-674,139
| -62% | -$35.3M |
|
262
Tenet Healthcare
THC
$20.5B
| $21.8M | 0.12% |
+123,670
| New | +$18.6M |
|
263
Lithia Motors
LAD
$8.47B
| $21.8M | 0.11% |
64,388
+19,675
| +44% | +$6.09M |
|
264
Kymera Therapeutics
KYMR
$8.51B
| $21.7M | 0.11% |
498,111
-27,134
| -5% | -$934K |
|
265
Equinox Gold
EQX
$7.06B
| $21.7M | 0.11% |
+3,779,266
| New | +$24.5M |
|
|
KALV
266
DELISTED
KalVista Pharmaceuticals
KALV
| $21.7M | 0.11% |
1,920,664
+303,195
| +19% | +$3.71M |
|
267
ICU Medical
ICUI
$4.21B
| $21.7M | 0.11% |
164,305
+3,395
| +2% | +$460K |
|
268
Avery Dennison
AVY
$13B
| $21.6M | 0.11% |
123,280
+55,182
| +81% | +$9.67M |
|
269
United Airlines
UAL
$39.4B
| $21.4M | 0.11% |
+269,227
| New | +$19.8M |
|
270
Waters Corp
WAT
$37B
| $21.4M | 0.11% |
61,411
-14,150
| -19% | -$4.86M |
|
271
Lockheed Martin
LMT
$134B
| $21.4M | 0.11% |
46,238
+17,369
| +60% | +$8.13M |
|
272
TG Therapeutics
TGTX
$7.96B
| $21.4M | 0.11% |
594,620
+61,486
| +12% | +$2.29M |
|
273
Uber
UBER
$143B
| $21.3M | 0.11% |
228,384
-353,051
| -61% | -$29.1M |
|
274
Cleveland-Cliffs
CLF
$6.57B
| $21M | 0.11% |
2,761,463
+352
| +0% | +$2.62K |
|
275
Immatics
IMTX
$1.18B
| $20.9M | 0.11% |
3,877,631
+2,193,346
| +130% | +$10.9M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.